NASDAQ · Drug Manufacturers - General

Scilex Holding Company (SCLX) Stock

$6.93 +1.24% NASDAQ: SCLX Healthcare

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles.

Valuation

MetricValue
Price$6.93
Market Cap$58.80M
P/E Ratio-0.18
P/B Ratio-0.19
P/S Ratio1.72
EPS (TTM)$-36.48
52-Week High$21.34
52-Week Low$2.62
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE190.13%
ROA-142.92%
ROCE132.94%
Gross Margin-910.00%
Operating Margin-906.67%
Net Margin-12.39%
Debt/Equity-0.43
Current Ratio0.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$31.0M$38.0M$47.0M$57.0M$30.0M
Operating Profit$-36.0M$-51.0M$-105.0M$-83.0M$-272.0M
Net Profit$-88.0M$-23.0M$-114.0M$-73.0M$-359.0M
EPS$-23.29$-6.09$-44.85$-19.43$-36.48
Op Margin-114.4%-133.1%-225.6%-147.4%-900.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$78.0M$87.0M$101.0M$93.0M$365.0M
Total Liabilities$302.0M$50.0M$274.0M$286.0M$577.0M
Cash$4.0M$2.0M$4.0M$3.0M$5.0M
Borrowings$155.0M$1.0M$128.0M$38.0M$133.0M

Latest News

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP GlobeNewswire · Jul 7, 2026 Scilex, Vera Therapeutics rise premarket; Strategy gains Investing.com · Jul 6, 2026 Scilex Shares Jump After Securing $100 Million Strategic Investment Proposal (SCLX) InvestorsHub · Jul 6, 2026 Scilex Agrees to Sell $100 Million in Newly Issued Shares to Kazakhstan-Based iHolding MT Newswires · Jul 6, 2026 Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP GlobeNewswire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-29.0M$-21.0M$-21.0M$19.0M$4.0M
Investing Cash Flow$0$-4.0M$-1.0M$-3.0M$4.0M
Financing Cash Flow$48.0M$52.0M$-13.0M$1.0M$-31.0M
Net Cash Flow$-1.0M$-2.0M$3.0M$-1.0M$2.0M
Free Cash Flow$-29.0M$-23.0M$-21.0M$19.0M$4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.43
FCF Yield6.80%
Quick Ratio0.07
Interest Coverage-24.73
Return 1Y116.92%
Return 3Y-92.93%
Return 5Y-95.80%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
ALEC $1.52 +0.33% -1.58 $168.20M 0.00%
CTOR $0.75 -0.92% -2.44 $70.01M 0.00%
INO $1.04 +0.97% -2.73 $55.73M 0.00%

About Scilex Holding Company

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Scilex Holding Company is led by CEO Henry H. Ji, employs 115 people, headquartered in US, publicly traded since 2021.

Scilex Holding Company (SCLX) stock trades at $6.93 with a market capitalization of $58.80M. The stock is valued at a price-to-earnings (P/E) ratio of -0.18, price-to-book of -0.19, price-to-sales of 1.72. Over the past 52 weeks the stock has ranged between $2.62 and $21.34, and currently trades 67.5% below its 52-week high.

On profitability, Scilex Holding Company generates a return on equity (ROE) of 190.13% — well above the market average, a sign of a high-quality business, return on capital employed of 132.94%, an operating margin of -906.67%, a net profit margin of -12.39%.

Official website: www.scilexholding.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides